NAPA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Senetek PLC , a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Neil Sadick presented on Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.
In his presentation to the Academy, Dr. Sadick, a prominent New York dermatologist, outlined the therapeutic benefits of Senetek’s Pyratine-6(TM) for the treatment of aging skin. Dr. Sadick reviewed clinical data demonstrating the ability of Pyratine-6(TM) to ameliorate the visible signs of skin aging and significantly reduce erythema -- redness of the skin caused by capillary congestion.
In independent clinical trials at the University of California, Irvine and RCTS, an independent laboratory in Irving, Texas, Pyratine-6(TM) demonstrated significant efficacy in the treatment of fine wrinkles, skin roughness, acne lesions, overall skin aging, and significantly reduced erythema as early as two weeks from onset of use. Pyratine-6(TM) was also shown to increase skin moisture content and was well tolerated by all subjects producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12-week study periods.
Frank Massino, Chairman and Chief Executive Officer of Senetek stated, “We are very pleased by the recognition Pyratine-6(TM) has received at this important dermatological symposium.”
About Senetek PLC
Senetek PLC is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company’s extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.
For more information, visit the company’s website at http://www.senetekplc.com.
This news release contains statements that may be considered ‘forward- looking statements’ within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
CONTACT: William F. O’Kelly, Chief Financial Officer of Senetek PLC,
+1-707-226-3900, ext. 102
Web site: http://www.senetekplc.com/
